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Abstract 
 
An Examination of the Association between Sleep and Neurocognitive Performance in 
Relapsing-Remitting Multiple Sclerosis 
 
Jessica Zamzow 
 
 
 
 
 
Individuals with MS experience a high rate of sleep disorder symptoms and a high 
frequency of cognitive deficits. Both sleep disturbance and cognitive impairment can 
have a profound impact on perceived quality of life and functional living. While it is well 
established that sufficient sleep quality and quantity are necessary for optimal cognitive 
performance in healthy adults, the relationship between sleep and cognitive function has 
been largely understudied in MS. The present study is an examination of the association 
between sleep and cognitive function in individuals with MS through the use of objective 
and subjective measures of sleep and neurocognitive function. Fifty participants with 
relapsing-remitting MS completed two weeks of standardized sleep diary and wore 
actigraphy for fourteen consecutive days. Participants then completed a two-hour testing 
session comprised of neurocognitive measures and questionnaires. Results indicated that 
sleep duration, sleep efficiency, and sleep quality did not predict performance on tests of 
processing speed, attention, psychomotor vigilance, working memory, short-term 
memory, or verbal fluency. Symptoms of all sleep disorders (i.e., insomnia, sleep apnea, 
and RLS/PLMD) were associated poorer cognitive function in individuals with MS.  
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CHAPTER 1: INTRODUCTION 
 Multiple Sclerosis (MS) is a chronic and incurable disease of the central nervous 
system (CNS) affecting over 2.3 million people worldwide (National MS Society). There 
are four disease courses within MS (i.e., primary progressive, secondary progressive, 
relapsing remitting, and progressive-relapsing) (National MS Society). Approximately 
85% of individuals with MS have relapsing-remitting MS, characterized by acute attacks 
and periods of full or partial remission (National MS Society). Diagnosis of MS requires 
the presence of two or more distinct lesions in the CNS resulting from two or more 
attacks and cannot be explained by another diagnosis (Markowitz, 2013). Individuals 
with MS primarily experience motor and sensory symptoms related to the regions of the 
brain and spinal cord affected by the disease (Markowitz, 2013). In addition, many 
individuals with MS experience other neurobehavioral symptoms, such as fatigue, 
depression, sleep disturbance, and cognitive dysfunction (see Strober & Arnett, 2013 for 
review).  
The overarching goal of this project is to examine the nature of the relationship 
between sleep and neurocognitive function in relapsing-remitting MS. Individuals with 
MS experience a high rate of sleep disorders and sleep continuity disturbance. A high 
frequency of individuals with MS also experience cognitive impairment. Both sleep 
disturbance and cognitive impairment can have a profound impact on perceived quality of 
life and functional living in individuals with MS (Trojan et al., 2012). While it is well 
established that sufficient sleep quality and quantity are necessary for optimal cognitive 
performance in healthy adults, the relationship between sleep and cognitive function has 
been largely unstudied in MS. Accordingly, the proposed study aims to examine the 
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relationship between sleep and cognitive function for individuals with MS through the 
use of (1) objective and subjective measures of sleep and (2) symptoms of sleep disorders 
and neurocognitive function. 
Sleep Disorders and Sleep Continuity Disturbance in MS  
It is estimated that over 50% of people with MS report sleep disturbance 
characterized by difficulty initiating and maintaining sleep (Bamer, Johnson, Amtmann, 
& Kraft, 2008; Merlino et al., 2009; Tachibana et al., 1994). There is a great degree of 
heterogeneity in the types of sleep disturbance experienced by individuals with MS, 
including circadian rhythm disorders, insomnia, sleep-related movement disorders, sleep 
apnea, parasomnias, narcolepsy, and hypersomnolence disorder. With the exception of 
insomnia and movement-related sleep disorders, the prevalence data on each of these 
disorders within the MS population is limited (see Table 1). Sleep disturbance in this 
population tends to be attributed to several somatic symptoms (e.g., bladder incontinence, 
pain, muscle spasms), pharmacological side effects (e.g., Beta-Interferon, 
Methylprednisolone, and Amantadine), mood symptoms (e.g., worry, anxiety, depressed 
mood), and/or lesions in specific regions of the central nervous system (Caminero & 
Bartolome, 2011; de Souza et al., 2003; Oka et al., 2004; Strober & Arnett, 2013; 
Tippmann-Peikert, Boeve, & Keegan, 2006). Finally, approximately 36% of individuals 
with MS use prescription or over the counter sleep aids at least once or twice a week 
Bamer et al. (2008). 
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 Sleep disorders and sleep continuity disturbance can cause daytime sleepiness, 
fatigue, and cognitive dysfunction. Approximately 30% of individuals with MS report 
excessive daytime sleepiness (Stanton, Barnes, & Silber, 2006) and an estimated 75–90% 
of individuals with MS experience significant fatigue (Fisk et al., 1994; Freal, Kraft, & 
Coryell, 1984; Krupp & Pollina, 1996). Excessive sleepiness and fatigue are significant 
and disabling symptoms that can interfere with quality of life and functionality. Although 
sleepiness and fatigue may be attributed to numerous factors in persons with MS (e.g., 
immune factors, mood, medication side effects), sleep disturbance is also associated with 
fatigue and daytime sleepiness (Branas et al., 2000; Stanton et al., 2006). Importantly, 
Table 1. 
Prevalence of Sleep disorders in Multiple Sclerosis  
Sleep Disorder Prevalence in MS Prevalence in the general adult population 
Insomnia >40% 1 10-30%2,3 
Circadian rhythm sleep disorders Unknown Approximately 1%3 
Restless legs syndrome (RLS) 12.1–57.5%5  2.6–18.3%5 
Periodic limb movement disorder (PLMD) 37%6  3.9%7 
Sleep-related breathing disorders (SBD) Unknown* 10% to 17%8 
Hypersomnolence Disorder Unknown Estimated 1%9 
Narcolepsy Unknown  <1%10 
REM behavior disorder (RBD) 1.4%11 <1%11 
Note. Modified from Lunde, et al., 2013.  
1. Stanton Barnes, & Silber, 2006; Tachibana et al., 1994 2. Brass, Duquette, Proulx-Therrien, & Auerback, 2010; 
Fleming & Pollack, 2005; Ohayon & Reynolds, 2009  3. Roth, 2007 4. Ando, Kripke, & Ancoli-Israel, 1995  5. 
Schurks & Bussfeld, 2013  6. Dyken, Afifi, & Lin-Dyken, 2012  7. Ohayon & Roth, 2002   8. Peppard et al., 2013  
9. American Psychiatric Association, 2013 10. Hublin et al., 1994  11. Gomez-Choco et al., 2007  
*Estimated 38-56% of individuals with MS screened high-risk for obstructive sleep apnea according to the STOP-
BANG questionnaire (Braley, Segal, & Chervin, 2014; Brass, Li, Auerback, 2014;  Dias and colleges, 2012) as 
opposed to 28% in the general adult population (Chung et al., 2008). 
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insomnia, sleep-disordered breathing, and narcolepsy have each been linked to cognitive 
deficits in otherwise healthy adults (Fulda & Schulz, 2001) (See below for a review of the 
literature on cognitive functioning in specific sleep disorders). 
Neurocognitive Function in MS 
Cognitive impairment is a prominent symptom in MS, occurring in approximately 
45–65% of persons with MS (Rao, Leo, Bernardin, & Unverzagt, 1991). Cognitive 
deficits in this population are heterogeneous across patients, but primarily result in 
deficits in memory, processing speed, attention, and executive functioning (Rao, Leo, 
Bernardin, et al., 1991). Even mild impairments in cognitive function can significantly 
interfere with a person’s success in completing activities of daily living, including 
personal care, driving ability, social functioning, and meeting occupational demands 
(Rao, Leo, Ellington, et al., 1991; Ruet et al., 2013; Schultheis, Garay, & DeLuca, 2001). 
Sleep and Neurocognitive Function in Healthy Adults 
Sufficient sleep quality and duration are necessary for optimal cognitive 
performance in healthy adults (see Waters & Bucks, 2011 for review). Research 
investigating sleep and cognitive performance in healthy adults has found the largest 
effect of sleep deprivation on tasks of attention, vigilance, and working memory (Lim & 
Dinges, 2010).  Insufficient sleep is also related to increased reaction time, and impaired 
short-term memory, expressive language (or fluency), and executive functioning (see 
Waters & Bucks, 2011 for review). Functional neuroimaging research has found 
abnormal activation in the prefrontal and parietal cortex and thalamus (attentional 
system) following sleep deprivation (Drummond et al., 2005; Thomas et al., 2000; 
Tomasi et al., 2009; Waters & Bucks, 2011). 
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Several hypotheses have been proposed to describe the basis for neurocognitive 
deficits following sleep deprivation. For example, the “sleep lapse hypothesis” suggests 
that micro-sleeps result in lapses in attention that can manifest in errors of omission on 
tests of sustained attention and vigilance (Durmer & Dinges, 2005). However, this does 
not explain the entirety of the problems associated with sleep deprivation. For example, 
there is an overall slowing of response time following sleep loss that is independent of 
detectable micro-sleeps. Furthermore, many studies have found diminishing endurance 
during long tasks, poor inhibitory control, and greater variation in performance across the 
day (Durmer & Dinges, 2005). This variability may be, in part, related to circadian 
variations in alertness and ability to compensate for sleep loss. As a result, it is thought 
that several factors contribute to measurable decrements in cognitive performance 
associated with insufficient sleep duration. 
Thus far, sleep research has primarily focused on problems related to short sleep 
duration (e.g., less than 6.5 hours), with little attention paid to functional performance in 
long sleepers (e.g., greater than 7.5 hours, as defined by Grandner and Drummond, 2007). 
Emerging evidence has indicated negative effects of experimentally controlled sleep 
extension in healthy adults. Taub (1980) used a sleep extension protocol that 
implemented a within subjects design in which sleep was recorded in a laboratory setting 
on two different nights 1.) a night of 8 hours of controlled sleep duration and 2.) a night 
of “ad lib” sleep duration and timing in which participants received an average of 9.6 
hours of sleep (range 8.6-13.3 hours). The order of the two nights was counterbalanced 
and each participant received five nights of recovery sleep in between laboratory 
recordings. Following the night of ad lib extended sleep, participants reported feeling 
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sleepier, and showed slowed reaction time and poorer immediate recall of verbal 
information (Taub, 1980). These findings were consistent with Taub’s (1971) previous 
findings in an earlier study in which participants were given an 8 hour and 11 hour 
window of sleep opportunity and instructed to sleep for as long as they would like. All 
participants slept longer when given greater opportunity for sleep (M = 9.1 versus M = 
7.1) and showed an increase in reaction times on a vigilance test (Taub, Globus, Phoebus, 
& Drury, 1971). In addition, there is also evidence of small effects of both long and short 
sleep duration on objective and subjective cognitive function in the general adult 
population (Kronholm et al., 2009). Individuals with MS engage in heterogeneous sleep 
behaviors, including short sleep duration, long sleep duration, sleep fragmentation, and 
excessive sleepiness. Thus, it is important to consider the effects of the spectrum of sleep 
behavior on cognitive performance. 
Finally, it is well established that there is a large degree of interindividual 
variability in the behavioral and emotional effects of sleep loss. Researchers have 
suggested that neurologically healthy individuals with greater “cognitive reserve” may be 
less vulnerable to the cognitive impact of sleep deprivation, enabling them to engage 
additional neuronal recourses to counter the effects of sleep loss (Van Dongen, Baynard, 
Maislin, & Dinges, 2004). Cognitive reserve most often refers to premorbid intelligence 
and/or exposure to an intellectually stimulating environment, typically characterized by 
higher levels of education. The benefits of cognitive reserve are based on the idea that 
those with greater cognitive faculty will suffice better in the face of factors that impact 
cognitive function. Van Dongen and colleagues (2004) argue that cognitive reserve could 
buffer against potential impairments associated with sleep deprivation. That is, 
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individuals with higher baseline cognitive functioning may experience a less significant 
effect of sleep difficulties on cognitive function. Past research across multiple 
populations has indicated that higher cognitive reserve buffers against cognitive effects of 
neurodegenerative processes. The same logic may also describe resilience to the 
combined threat of cognitive impairments in multiple processes (e.g., MS and a sleep 
disorder, fragmentation, or deprivation). Those with lower premorbid functioning are 
likely to be more vulnerable to the effects of the MS disease process and the effects of 
sleep disorders on cognition. Furthermore, because the neurodegenerative process 
decreases baseline cognitive ability, individuals with cognitive impairments related to 
neurologic insult or disease may be more vulnerable to the daytime cognitive effects of 
sleep disorders, fragmentation, or deprivation than neurologically healthy adults. See 
figure one for proposed model of the relationship between sleep and cognitive function in 
MS. 
Neurocognitive Function Associated with Sleep Disorders 
 Insomnia Disorder.  Insomnia Disorder is characterized by difficulties falling 
asleep or maintaining satisfactory sleep despite opportunity for adequate sleep (American 
Psychiatric Association, 2013). Studies investigating cognitive performance in 
individuals with Insomnia Disorder have found conflicting evidence of deficits within 
specific domains of cognitive functioning. However, a recent meta-analysis including 24 
studies of cognitive function in individuals with insomnia reported mild to moderate 
impairments in specific domains of cognitive function (Fortier-Brochu, Beaulieu-
Bonneau, Ivers, & Morin, 2012). Individuals with insomnia performed more poorly than 
controls on tasks measuring working memory, verbal memory, novel problem solving, 
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and attention (see table 2; Fortier-Brochu, 2012). The results of the meta-analysis also 
suggest that individuals with insomnia disorder perform comparably to normal sleepers 
on measure of psychomotor ability, procedural memory, verbal ability, mental flexibility, 
and intelligence (Fortier-Brochu et al., 2012). 
Sleep Apnea. Obstructive sleep apnea (OSA) syndrome is characterized by 
recurrent periods of airway restriction during sleep (American Academy of Sleep 
Medicine, 1997). Central sleep apnea is characterized by periods of halted or reduced 
ventilation related to disruption in communication between the lungs and the brain 
(American Academy of Sleep Medicine, 1997). Both central and obstructive sleep apneas 
are associated with reduced blood oxygen levels and can result in fragmented sleep 
(American Academy of Sleep Medicine, 1997). Apneic events can cause repeated loss of 
oxygen to the brain, which can cause neuronal damage. In patients with sleep apnea, 
neuropsychological impairments in attention, memory, executive function, and 
constructional abilities are associated with reduced grey matter volume in brain regions 
associated with these functions (i.e., the hippocampal enthorinal cortex, posterior parietal 
cortex, and superior frontal gyrus) (N. Canessa et al., 2011). Likewise, there is evidence 
that sleep apnea can create a pro-inflammatory state, and these inflammatory bio-markers 
appear to be related to cognitive dysfunction in patients with sleep apnea (Haensel et al., 
2009). The sleep fragmentation that occurs in sleep apnea can result in excessive daytime 
sleepiness and cognitive effects similar to partial-chronic sleep deprivation. A meta-
analysis of cognitive dysfunction in OSA revealed moderate to large effects on tests of 
sustained attention, psychomotor speed, working memory, novel problem solving, 
inhibitory control, verbal fluency, and safe driving ability (for review see Fluda & 
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Schulz, 2010). In addition, OSA appears to have a small effect on delayed recall, and 
processing speed (See table 2; for review see Fluda & Schulz, 2010). Neurocognitive 
impairments in sleep apnea have been associated with both sleep fragmentation and 
hypoxemia (see Aloia, 2004 for review). Furthermore, the vascular effects of OSA may 
also contribute to cognitive deficits in this population (Aloia, 2004). Finally, sleep apnea 
appears to result in greater cognitive deficits in neurologic populations, including 
traumatic brain injury and Alzheimer’s disease (Ancoli-Israel et al., 2008; Wilde et al., 
2007). 
Importantly, successful treatment of sleep apnea appears to result in 
improvements in global cognition, attention, executive function, memory, and 
constructional abilities and reversal of grey and white matter volume loss (Aloia et al., 
2004; N. Canessa et al., 2011; Castronovo et al., 2014). In fact, improvements in 
neuropsychological functioning have been associated with increases in grey matter 
volume in the hippocampus, orbitofrontal cortex, and superior frontal gyrus (N. Canessa 
et al., 2011) and can also likely be attributed to reductions in sleep fragmentation (Aloia 
et al., 2004). Treatment of sleep apnea has also been associated with improvements in 
cognitive function in Alzheimer’s Disease (Ancoli-Israel et al., 2008).  
Movement-Related Sleep Disorders. RLS is characterized by unpleasant 
sensations in the lower extremities accompanied by an urge to move one’s legs that 
worsens with inactivity and is relieved by movement (American Academy of Sleep 
Medicine, 1997). PLMD is characterized by periodic instances of limb movements during 
sleep (American Academy of Sleep Medicine, 1997). RLS and periodic limb movement 
disorder (PLMD) are separate disorders that often co-occur. Most individuals with RLS 
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experience period limb movements during sleep (American Academy of Sleep Medicine, 
1997). PLMs often cause awakenings or arousals although the individual may not be 
aware of the sleep disturbance (American Academy of Sleep Medicine, 1997). Both RLS 
and PLMD can cause significant sleep disturbance and excessive daytime sleepiness 
(American Academy of Sleep Medicine, 1997). Current research suggests that patients 
with untreated RLS and PLMD show cognitive deficits similar to one night of sleep 
deprivation (Pearson et al., 2006). Dopaminergic agents are used to treat RLS and PLMD 
(Hening et al., 2004). As a result, researchers believe that persons with RLS and PLMD 
may have altered dopaminergic function. If so, this too could have an effect on cognitive 
functioning. 
Narcolepsy. Narcolepsy is characterized by episodes of excessive sleepiness 
(American Academy of Sleep Medicine, 1997). Individuals with narcolepsy may also 
experience episodes of irresistible sleep of short duration, brief episodes of cataplexy, 
hypocretin deficiency, and/or REM intrusions into wakefulness (i.e., hypnopompic or 
hypnagogic hallucinations) (American Academy of Sleep Medicine, 1997). Case studies 
indicate that narcolepsy in MS may be related to hypothalamic lesions (Iseki, Mezaki, & 
Oka, 2002; Oka et al., 2004). Cognitive impairments associated with narcolepsy are 
greatly influenced by daytime sleepiness (for review see Fluda & Schulz, 2010). Studies 
have consistently found decreased vigilance in those with narcolepsy compared to 
controls (for review see Fluda & Schulz, 2010). In addition, some studies have found 
decrements in attention and memory, although more research is needed to elucidate the 
extent of impairments in these and other domains of cognitive functioning (See table 2; 
for review see Fulda & Schulz, 2010). Individuals with narcolepsy also show reduced 
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driving performance compared to controls (Wilde et al., 2007).  
 
Circadian Rhythm Disorders. Circadian rhythm disorders are characterized by a 
misalignment between an individual’s endogenous sleep-wake pattern and their required 
sleep-wake schedule (American Psychiatric Association, 2013). This results in daytime 
sleepiness and/or insomnia that cause significant distress or impairments in functioning 
(American Psychiatric Association, 2013). Thus far, there have been no studies looking at 
neurocognitive performance in individuals with circadian rhythm disorders compared to 
healthy controls. However, there is evidence that individuals with advanced or delayed 
circadian rhythms may perform better in the morning or evening, respectively (Adan et 
al., 2012). This appears to be related to circadian peaks and low points in alertness 
throughout the day. The extent to which cognitive domains are susceptible to circadian 
variation is not fully known, but performance on measures of attention, working memory, 
inhibitory, and self-monitoring have each been shown to vary with circadian timing in 
healthy adults (Valdez, Ramirez, & Gracia, 2012).  
Table 2. 
Summary of cognitive impairments associated with specific sleep disorders 
 
Sleep disorder Associated cognitive impairments  Citation 
Insomnia Disorder Working memory, verbal memory, novel problem 
solving, and attention/vigilance  
Fortier-Brochu et al., 2012 
Sleep Apnea Sustained attention, psychomotor speed, working 
memory, novel problem solving, inhibitory control, 
verbal fluency, verbal memory, and safe driving 
ability 
For review see Fluda & Schulz, 2010; 
Bucks, Plaithe, & Eastwood, 2013  
RLS and PLMD Verbal Fluency and mental flexibility  Pearson et al., 2006 
Narcolepsy Vigilance, attention, memory, and driving ability For review see Fulda & Schulz, 2010; 
Wilde, 2006  
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REM Behavior Disorder. REM behavior disorder (RBD) is characterized by a 
lack of atonia during REM sleep and complex motor behaviors associated with dreaming 
(American Academy of Sleep Medicine, 1997). RBD often occurs with synuclienopathies 
such as Parkinson’s and Lewy Body Dementia. There is evidence that individuals with 
idiopathic RBD may experience visuo-spatial impairments, even in the absence of 
cognitive complaints (Ferini-Strambi et al., 2004). Cognitive impairments in RBD do not 
appear to be related to sleep fragmentation (Ferini-Strambi et al., 2004); rather it is likely 
that idiopathic RBD may be part of the prodromal stages of underlying neuropathology. 
In fact, “idiopathic” RBD often progresses into Lewy Body Dementia (Schenck, Boeve, 
& Mahowald, 2013; Schenck & Mahowald, 2002).  Therefore, it is unlikely that RBD in 
itself impacts cognitive function; rather the etiology of RBD may be linked to insidious 
pathology that results in cognitive decline. 
Sleep and Neurocognitive Function in MS 
Sleep deprivation in healthy adults can cause diminished function in some of the 
same cognitive domains most commonly affected in MS, including processing speed, 
attention, and executive function (Lim & Dinges, 2010; Waters & Bucks, 2011). Recent 
studies have begun to look at the relationship between sleep and cognitive function in 
MS. First, Lehmann and colleagues (2013) reported on the relationship between sleep 
quality, (as measured by the Pittsburgh Sleep Quality Index; PSQI), fatigue and cognitive 
function in MS. This sample included 42 participants with relapsing-remitting MS. To be 
included in the study participants needed to have been free of relapse or corticosteroid 
treatment for one month prior to study enrollment due to the acute changes in sleep and 
function during relapse and steroidal treatment, which is not likely to generalize beyond 
	   13	  
the acute relapse. Participants in this study did not take sedatives and were prohibited 
from stimulant use (e.g., Modafinil) on the day of the study. Researches used a single 
cognitive measure of sustained working memory, consisting of a series of three 10-
minute N-Back (2-back) tasks broken up by periods of either relaxation or stimulation. 
This sustained performance was intended to induce cognitive fatigue. The results of this 
study indicated that (1) MS patients who reported high levels of fatigue performed more 
poorly than those without fatigue and (2) those who reported poor sleep quality 
performed comparably to those without sleep difficulties at the beginning of the working 
memory (n-back) task, but showed a slowing of response time over repeated trials 
(Lehmann et al., 2013). Second, preliminary work in our lab (N = 38) suggested that 
longer sleep duration and greater time spent in bed were related to slower processing 
speed and reduced sustained and divided attention in patients with MS (Zamzow et al., 
2014). Both studies relied on retrospective, self-report measures of sleep quality and 
quantity (PSQI) on a limited battery of neuropsychological tests. Third, Sater and 
colleages (2015) used one night of polysomnography to examine sleep and cognitive 
function in MS. Cognitive function was measured using the “NeuroTrax” software to 
assess memory, executive function, information processing, verbal fluency, attention, 
motor ability, and “global cognition”. Results indicated that sleep efficiency (i.e., the 
ratio of time asleep to total time spent in bed, calculated as 100*[total sleep time/time in 
bed]) was positively associated with executive function, information processing, and 
“global cognition”. The current study aims to build upon the limitations of these critical 
prior studies by including both objective and subjective daily prospective data on sleep 
continuity, examining the association between specific sleep disorder symptoms and 
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cognitive function, and by including a more comprehensive and clinically meaningful 
cognitive battery. 
Aims and Hypotheses 
Our primary aim is to examine the relationship between sleep and neurocognitive 
function among individuals with relapsing-remitting MS as measured by subjective and 
objective measures of sleep behavior (aim 1). It is hypothesized that (a) greater sleep 
disturbance, as measured by the PSQI global score, would be associated with poorer 
performance on neurocognitive measures of processing speed, attention, vigilance, 
working memory, short-term memory, and verbal fluency and (b) shorter sleep duration 
and lower sleep efficiency would be associated with poorer performance on 
neurocognitive measures (i.e., processing speed, attention, vigilance, working memory, 
short-term memory, and verbal fluency). Both sleep duration and sleep efficiency were 
measured objectively using an accelerometer and derived from sleep diary. 
Second, as an exploratory aim, we seek to qualify the nature of the association 
between neurocognitive function and specific sleep problems (e.g., insomnia measured 
using the Insomnia Severity Index, symptoms of movement-related sleep disorders as 
captured by the Global Sleep Assessment Questionnaire, and risk for sleep apnea as 
measured by the STOP-BANG questionnaire ≥3) in relapsing-remitting MS. We 
hypothesized that insomnia symptoms would be negatively related to reduced 
performance on neurocognitive measures of attention/vigilance, memory, working 
memory, and mental flexibility; symptoms of movement related sleep disorders were 
associated with reduced attention, psychomotor vigilance, working memory, verbal 
fluency, memory, and mental flexibility; and elevated risk for sleep apnea would be 
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related to reduced attention, working memory, verbal fluency, inhibitory control, and 
psychomotor speed. 
Significance of the Present Study 
To date, sleep research in this population has primarily focused on the prevalence 
of sleep disorders and the relationship between sleep and fatigue. The prevalence of 
certain sleep disorders and sleep continuity disturbance appears to be much higher in MS 
than in the general population. Daytime sleepiness and fatigue are obvious daytime 
consequences of sleep problems, but it is important to also understand the potential 
effects of sleep disturbance on cognitive function. Furthermore, sleep appears to play a 
role in brain plasticity, a critical process for individuals with neurologic disease (Frank, 
Issa, & Stryker, 2001; Tononi & Cirelli, 2001; Walker & Stickgold, 2006). Sleep 
disorders are highly treatable and therefore may pose as a modifiable risk factor for 
cognitive impairment in this population. Studies have shown that sleep-dependent 
cognitive deficits may be reversed once individuals with sleep apnea return to normal, 
healthy sleep (for review see Aloia, et al., 2004). This suggests a potential point for 
intervention in neurologic populations, such as MS, who may experience an exacerbation 
of cognitive difficulties related to poor sleep that might be remediated by treatment. 
Finally, poor sleep quality and cognitive impairment can each negatively affect perceived 
quality of life (QoL) and functional living in individuals with MS (Glanz et al., 2010; 
Merlino et al., 2009). Understanding the association between sleep and neurocognitive 
function has significant implications for the future development of rehabilitation efforts 
that can improve quality of life and everyday function of individuals with MS. 
CHAPTER 2: METHODS 
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Participants  
A power analysis based on a moderate effect size generated from preliminary data 
collected in our laboratory (f2 = 0.15, α = 0.05, 1–β = 0.80) suggested a sample size of 77 
participants would be needed in order to detect an effect in this study. However, previous 
studies in this population, using similar subjective measures of sleep behavior, have 
found significant effects with between 38-42 participants. Therefore, we collected data on 
50 participants with relapsing-remitting MS for this study.  
Participants were required to be between the ages of 18-55, diagnosed with 
relapsing-remitting MS for at least six months, on a stable medication regimen, including 
no new medications or discontinuing medications for 30 days prior to enrollment and 
throughout the course of the study (two weeks). Likewise, participants were not able to 
enroll within 30 days of having had a relapse. The age of 55 was chosen as the upper 
limit due to concerns about cognitive decline as a result of normal aging. Participants 
were not included in the study if they report prior head injury or other neurologic 
disorder, current severe psychiatric illness (including schizophrenia, manic, or psychotic 
episode), drug, or alcohol dependence. A total of 64 participants were screened to obtain 
the final sample. Eleven participants who were screened were not be eligible due to age 
(n = 8), substance dependence (n = 1), and less than 6 months since diagnosis (n = 1). 
One participant dropped out of the study due to an exacerbation of symptoms within 
during the course of their participation in the study.  
 
Measures 
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Objective Sleep Measurement. Actigraphy is a small, device, typically worn on 
the wrist, which uses motion sensors to measure movement continuously throughout the 
day and night. In this study, the Actiwatch Spectrum by Philips Respironics were used to 
measure sleep onset latency (SOL), nighttime awakenings (WASO), total sleep time 
(TST), and sleep efficiency (SE). Motion was calculated in 30-second epochs. 
Participants were asked to practice their regular daytime activities and sleep/wake 
schedule. Daytime naps and evening dozing off were recorded, but not included in the 
primary sleep analysis. Participants were instructed to press an event marker for lights out 
and lights on (i.e., sleep intervals). Summary variables for SOL, WASO, TST, and SE 
will be averaged over the number of days of actigraphy recorded. When participants 
completed more than 14 days of sleep monitoring, the last 14 days were used. Of the 50 
who completed sleep monitoring, the majority of participants (n = 46) completed the full 
14 days of actigraphy, one completed 13, two completed 12 days, and 1 completed 11 
days of recordings. Outliers were examined and removed from summary variables (see 
Results).    
Sleep Diary. This study included a standardized sleep diary based on expert 
consensus to gather participant’s self-reported estimates of sleep continuity, including 
bedtime, sleep onset latency frequency and duration of nighttime awakenings, final 
awakening time, time out of bed, subjective sleep quality, subjective feeling upon 
awakening, napping behavior, and daily medication use (Carney et al., 2012). Separate 
sleep diary forms were filled out in the morning and evening. See Appendix A for full 
sleep diary. When sleep diary data was missing, data was averaged over the number of 
days measured. 
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Questionnaires. The following questionnaires (see Table 3) were used to gather 
descriptive information, assess presence and severity of sleep disorders and disturbed 
sleep continuity, daytime sleepiness and fatigue, and mood. In addition, a demographic 
questionnaire was used to collect descriptive information about participant’s age, gender, 
ethnicity, educational history, employment status, shift work, health and psychiatric 
history, diagnosis sleep disorders (past or present), and medication usage. See appendix B 
for the demographic questionnaire. 
Table 3.  
Questionnaires  
 
Measure Description 
Insomnia Severity Index (ISI) 
 
The ISI is reliable measure composed of seven questions aimed to measure severity of 
insomnia symptoms over the past two weeks (Bastien, Vallieres, & Morin, 2001; C. M. 
Morin, Belleville, Belanger, & Ivers, 2011).  
Epworth Sl epiness Scale (ESS)  ESS is a self-report questionnaire that asks s bjects to rate the likelihood that they 
would f ll asleep in 8 specific situati ns of daily lif  (e.g., driving, watching TV, etc.). 
A total scor  greater than 10 sugg sts excessive daytime sleepiness (Johns, 1991). 
Excessive daytime sleepiness can result from insufficient sleep, sleep continuity 
disturbance, SDB, narcolepsy, idiopathic hypersomnia, and disease factors.  
STOP-BANG Questionnaire  The STOP-BANG Questionnaire categorizes people into “high risk” (≥ 3) or “low 
risk” (< 3) for OSA based on a series of yes/no questions.  The STOP-BANG 
questionnaire has high sensitivity but low sensitivity in detecting the presences of OSA 
(El-Sayed, 2012).   
Pittsburgh Sleep Quality Index  The PSQI is a reliable (α = .85) and valid self-report measure of subjective sleep 
quality and of sleep continuity using averages over the past month (Backhaus et al., 
2002). A global score of greater than 5 is used to classify people as “poor sleepers” 
(Buysse et al., 1989). The PSQI is a well-established, reliable, and valid measure of 
subjective sleep quality (Buysse et al., 1989; Grandner, Kripke, Yoon, & Youngstedt, 
2006).  
Global Sleep Assessment 
Questionnaire 
The GASQ is a standardized screener of sleep disorders. The GASQ has clinical cut-
off scores for insomnia (divided into primary and insomnia disorder co-morbid with a 
mental health disorder), OSA, RLS, periodic limb movement, parasomnias, and shift 
work disorder (T. Roth et al., 2002).  
Visual Analogue Scale of Fatigue  The VASF asks the participant to “rate how tired you are” on an analogue scale of 
0 to 10. 
Beck Depression Inventory-Fast 
Screen (for medical patients) 
 
The BDI-fs were used to assess for severity of Major Depression. 
State-Trait Anxiety Inventory 
 
The STAI were used to measure state (momentary/event-related) and trait anxiety 
(personality characteristic) (Spielberger et al., 1983). 
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Neurocognitive Measures. Cognitive assessments were selected on the basis of 1) 
cognitive domains often impacted in MS and 2) cognitive domains effect by sleep 
deprivation and disordered sleep (see Table 4). In addition, the National Adult Reading 
Test was used as a measure of premorbid intelligence. All neurocognitive measures were 
administered between the hours of 9:00am and 5:00pm. Participants were able to chose 
their testing time based on their preference. 
 
In addition, several measures were used to gather descriptive information about 
Note. Sleep continuity measures include sleep after onset latency, wake after sleep onset, total sleep time, and sleep 
efficiency. Both accelerometer and sleep diaries were measured over two consecutive weeks prior to in-lab neurocognitive 
assessment. 
Table 4. 
Neurocognitive Measures 
 
Measures Construct(s) 
National Adult Reading Test 
 
Estimate of pre-morbid intellectual function 
Oral Symbol Digit Modalities Test (SDMT) Information processing speed†§ 
Paced Auditory Serial Addition Test (PASAT) Attention, working memory, and mental arithmetic†§ 
N-back Attention and working memory  
Controlled Oral Word Association Test (COWAT) Verbal fluency§  
Psychomotor Vigilance Test (PVT) Alertness during sustained attention§ 
Useful Field of Vision Test (UFOV) Processing speed, selective attention, and divided attention. The UFOV computes 
a “driving risk” score (Ball & Roenker, 1998).†§ 
Stroop Color-Word Test Inhibition§ 
DKEFS Trail-Making Test Mental Flexibility§ 
Selective Reminding Test (SRT) Verbal learning and memory†,§ 
Note.  
†Cognitive domain commonly impacted in individuals with MS. 
§Impacted by sleep deprivation. 
A working memory composite score was created using an average of the four working memory tasks used in this study in order to reduce 
the change of a type I error.  
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the sample’s level of functioning and disease status. The oral-motor functioning was 
assessed using Maximum Repetition Rate of Syllables and Multisyllabic Combinations 
was used to measure oral motor speed (Kent, Kent, & Rosenbek, 1987) and was used as a 
covariate for language-based timed tests (i.e., oral SDMT, COWAT, and Animals). The 
9-Hole Peg Test and the Timed Walk Test were used as measures of upper and lower 
extremity functioning, respectively. The PASAT-3, 9-Hole Peg Test, and the Timed 
Walk Test were used to compute the Multiple Sclerosis Functional Composite Score 
(MSFC). The MSFC was used as a marker of functional capacity and symptom severity 
in MS (Fischer, Rudick, Cutter, & Reingold, 1999). Finally, self-reported Expanded 
Disability Status Scale (EDSS) were used as a measure of disease progression (Kurtzke, 
1983). The EDSS has been found to be highly correlated with neurologist’s ratings 
(Solari et al., 1993). 
Procedure  
Participants were recruited through an online advertisement on the NMSS website 
and local MS clinics. Participants were also selected from a database of participants who 
have participated in previous studies at Drexel University. After completing a brief phone 
screening, participants were scheduled for an intake session (approximately 60 minutes) 
in which they completed informed consent, receive a brief training on how to operate the 
accelerometer and how to complete the sleep diaries, and complete the descriptive 
questionnaire, the GSAQ, and the STOP-BANG Questionnaire. Participants also took 
home instructional materials for completing the sleep diary and operating the 
accelerometer. Participants were instructed to wear the actigraphy devices on their non-
dominant wrists for fourteen consecutive days. During this period participants recorded 
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information about time into bed, time to fall asleep, number and duration of nighttime 
awakenings, final wake time, and time out of bed each morning according to a 
standardized sleep diary each morning (see Appendix B for full sleep diary). They also 
completed a sleep diary in the evening, recording information about time spent napping, 
consumption of caffeine and alcohol, and subjective ratings of cognitive functioning each 
day. At the end of the two weeks of sleep monitoring participants came into the lab to 
return the Actigraphy devices and complete a two-hour testing session consisting of 
neurocognitive measures (approximately 90 minutes) and questionnaires (approximately 
30 minutes). Participants were asked to refrain from caffeine intake for at least four hours 
before coming in for the neurocognitive assessment. 
Aims 
Aim 1a. To examine whether self-reported sleep quality predicts performance on 
measures of processing speed, attention, vigilance, working memory, mental flexibility, 
and inhibitory control while controlling for age and mood as needed. Aim 1b. To 
examine whether total sleep time and sleep efficiency measured by an accelerometer and 
sleep diary predict performance on measures of processing speed, attention, vigilance, 
working memory, mental flexibility, and inhibitory control while controlling for age and 
mood as needed. Linear regressions were used to examine aim 1. In order to reduce the 
chance of a type one error with multiple comparisons, statistical significance will be 
interpreted at p < .05. Manual and oral motor speed will be controlled on timed written 
and spoken tests. Correlations were computed to identify additional covariates of age and 
mood.  
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Aim 2. To obtain estimates of effect size for the relationships between symptoms 
of specific sleep disorders and cognitive function. More specifically, we examined the 
relationship between the following: 1) Insomnia Severity Index total score measures of 
selective attention, verbal memory, and working memory; 2) Risk for sleep apnea as 
measured by ≥3 were correlated with attention, vigilance, verbal fluency, inhibition, 
verbal memory and working memory; 3) RLS and PLMD symptom severity were 
regressed on measures of executive functioning (i.e., attention, working memory, and 
verbal fluency). Preliminary analyses were undertaken to determine additional covariates 
(e.g., age, depression, anxiety, etc.), measure concordance of sleep diaries and 
accelerometer, and to test assumptions of linearity, homoscedasticity, and normality for 
all analyses. Correlations were used to explore the relationship between symptoms of 
sleep disorders and cognitive function. Covariates were identified and used consistent 
with the procedures described in aim 1. 
CHAPTER 3: RESULTS 
Sample Characteristics 
The final sample was comprised of 53 individuals diagnosed with relapsing-
remitting MS, 72% female. The majority of the sample was Caucasian (67%), followed 
by African America (20%), Hispanic/Latino (8%), Asian (2%), and Native American 
(2%). The sample was well educated, with a minimum of a high school education, 79% 
college educated or higher. The average level of disease severity, according to the self-
report EDSS, was in the moderate range of disability, with a high degree of variability 
across the sample (see Table 5). Age, gender, MS functional composite score, and 
disability status are typical for a sample of participants with relapsing-remitting MS. 
Table 5.  
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Sample Characteristics 
Descriptive Mean (Standard Deviation) Range 
Age 
 
Years of Education 
 
Years since MS diagnosis 
 
MS Functional Composite Score 
 
Expanded Disability Status Scale 
43.91 (7.28) 
 
15.81 (2.23) 
 
9.38 (6.48) 
 
0.01 (0.52) 
 
3.56 (1.90)	  
26 - 55 
 
12 - 20 
 
1 - 33 
 
-0.87 – 0.98 
 
0 – 7.5 
 
 
 Overall, 77% (n = 41) of the sample screened positive for clinically significant 
symptoms of one or more sleep disorder(s). Of those who screened positive, 53% 
screened positive for one sleep disorder, 31% screened positive for two, and 14% 
screened positive for all three types of sleep disorders (insomnia, sleep apnea, and 
movement-related sleep disorders). Of note, there is some expected overlap in symptoms 
of sleep disorders. For example, all sleep disorders are associated with greater sleepiness 
and fatigue, which is captured in measures of insomnia and sleep apnea. Therefore, 
screening positive for one sleep disorder can increase the likelihood that individuals will 
screen positive for a second or third sleep disorder using these measures. Full clinical 
assessment is required for a diagnosis. Table 6 outlines the prevalence of clinically 
significant symptoms of sleep disorders by sub-type. In addition, 55% (n = 36) of the 
sample was above the cut-off (>7) for poor sleep according to the PSQI. An item on the 
descriptive questionnaire described sleep disturbance in order of frequency: difficulty 
initiating or maintaining sleep, pain (including muscle spasms/cramping), excessive need 
for sleep (e.g., daytime sleepiness, “sleep too much”), and urinary frequency.  According 
to two weeks of sleep diary, the majority of the sample (88%) reported problems with 
urinary frequency disrupting their sleep on one or more nights, approximately half of the 
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sample reported worry (51%) or pain (46%) decreasing sleep quality one or more nights, 
and many participants reported muscle cramps (44%) or spasms (38%) interrupting their 
sleep on one or more nights. Amongst the 36 who reported significant sleep difficulties, 
13 participants reported having a diagnosed sleep disorder, including insomnia (n = 4), 
sleep apnea (n = 5), and RLS (n = 5). Of these 13 individuals, one reported a diagnosis of 
both sleep apnea and insomnia. Of those diagnosed with sleep apnea, two reported use of 
a CPAP or BiPAP most nights, one reported use of a mouth guard, one reported no 
current treatment, and one did not state. Four of five participants diagnosed with RLS 
were medicated for these symptoms. All four participants diagnosed with insomnia 
reported taking prescription of over the counter medications for sleep in the past month. 
Amongst the entire sample, 84% (n = 33) reported taking prescription of over the counter 
medications for sleep sometime in the past month. Gender differences in frequency were 
examined. The largest gender discrepancies in sleep disorder frequencies were in RLS 
and PLMD.  A higher percentage of women reported significant daytime sleepiness and 
fatigue. 
Table 6. 
Frequency Screened Positive  
Measures Sleep Disorders Female 
Frequency 
n = 38 
Male 
Frequency 
n = 14 
Sample 
Frequency 
n = 52 
Insomnia Severity Index Insomnia 35% 31% 34% 
STOP-BANG Sleep Apnea 37% 43% 39% 
RLS items of GSAQ RLS 40% 21% 35% 
 
PLMD items of GSAQ 
 
PLMD 
 
45% 
 
29% 
 
41% 
 
Epworth Sleepiness Scale 
 
Daytime Sleepiness 
 
49% 
 
23% 
 
42% 
 
Fatigue Severity Scale 
 
Fatigue 
 
76% 
 
67% 
 
71% 
Note. A positive screen for each sleep disorder was determined by the following cut-offs ISI > 14; STOP 
BANG > 3; GSAQ RLS > 0; GSAQ PLMD > 0; ESS > 10; FSS > 36 
 
Preliminary Analyses 
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Reliability. The internal reliability of the PSQI was measured using Cronbach’s 
Alpha, finding good internal consistency (α = 0.78). Correlations between objective and 
subjective sleep measures revealed a large, positive correlation between sleep diary and 
actigraphy TST (r = 0.68) and SE (r = 0.63). Past studies have found a similar degree of 
correlation between sleep diary and actigraphy TST (r = 0.63-.45) (Lauderdale et al., 
2008; Lockley, Skene, & Arendt, 1999; Tsuchiyama et al., 2003). On average, 
participants underestimated TST by 18 minutes and had comparable estimates of SE 
(within 1%). Congruency between sleep diary and actigraphy TST, but not SE, was 
weaker in those who screened positive for insomnia (n = 16; TST r = 0.64, SE r = 0.59) 
compared to those who did screen positive (n = 33; TST r = 0.75, SE r = 0.53). Previous 
studies have found that actigraphy may underestimate TST in individuals with insomnia 
due to long periods of time lying still while sleeping (Vallieres, 2003).  
Outliers. The outlier labeling rule as proposed by Hoaglin, Iglewicz, and Tukey 
(1986) was used to detect and remove outliers from the data. That is, outliers greater than 
1.5 times the difference between 25th% and 75th% quartiles of sample data were inspected 
for accuracy. Outliers were identified from PVT (n = 2) and N-Back 1-back condition (n 
= 2) and were removed due to suspected administration or recording errors on these 
computerized tasks. In addition, one participant fell asleep during the COWAT. Testing 
was discontinued for this participant who could not maintain wakefulness, and data from 
COWAT was not used. It is of note that this individual reported significant difficulty 
staying awake during the day as indicated by a high ESS score (ESS = 20), she was in the 
high risk range for sleep apnea (STOP-BANG = 4), and reported severe insomnia 
symptoms (ISI = 25). She reported a diagnosis of RLS that was controlled with 
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medications (i.e., she only experiences symptoms of RLS “sometimes”).  Although she 
screened positive for insomnia and sleep apnea, she denied diagnosis of these sleep 
disorders. Sleep diary sleep efficiency data were removed from two participants reporting 
significantly lower sleep efficiency on sleep diary compared to recordings on actigraphy 
device (i.e., with 42% and 21% disparity between sleep diary and actigraphy). These 
participants may have difficulty accurately estimating time spent awake in bed. 
Assumptions. Assumptions of normality, linearity, and homoscedasticity were 
tested for dependent variables included in all subsequent analyses. First, dependent 
variables were analyzed using the Kolmogorovo-Smirnov test of normality. Results 
indicated that the UFOV test of divided attention and the DKEFS set switching tests were 
skewed (p < 0.05). The UFOV was transformed using an inverse transformation and 
DKEFS scores were transformed using a log transformation. After these transformations 
the UFOV and DKEFS data were adequately normalized (P > .05). No non-linear 
relationships were detected upon examination of scatterplots. Data did not appear to 
violate he assumption of homoskedacicity based on visual inspection of P-P Plots.  
Sample Statistics. Mean sample total and subscale scores for sleep measures, 
sleep continuity variables, and cognitive variables are presented in Table 7. Mean ISI 
scores fell within the “sub-threshold” insomnia range. Mean STOP-BANG scores were 
below the cut-off for sleep apnea risk, but participants showed a wide range of sleep 
apnea risk on a scale of 0-8. Mean GSAQ total score suggests and a wide range of 
reported symptomology on a scale of 0-45. On average, participants reported a low level 
of RLS/PLMD items on a scale of 0-6 (see table 6).  Other GSAQ subscales included one 
item to measure parasomnias (M = 0.29, SD = 0.61, rage = 0-3), one item to measure 
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shift work (M = 0.50, SD = 0.64, rage = 0-2), two items to measure insomnia (M = 2.50, 
SD = 1.38, rage = 0-6), two items to measure sleep apnea (M = 0.81, SD = 1.17, rage = 0-
4), and one item measuring hypersomnia (M = 1.04, SD = 0.84, rage = 0-3). Mean PSQI 
total score was in the rage of poor sleep quality (> 7).  Average daytime sleepiness (ESS) 
was in the rage just within the normal range (normal < 10). 
As noted above, sleep diary and actigraphy total sleep time and sleep efficiency 
were highly correlated. As presented in Table 7, mean sleep duration was longer and 
sleep efficiency was slightly lower as measured by actigraphy.  Paired sample t-tests 
revealed significant differences between actigraphy and sleep diary in measures of 
WASO t(49) = 5.51 , p < 0.01) and TST (t(49) = 2.22, p < 0.05) .Average sleep onset 
latency (t(49) = 1.12, p = 0.27) and sleep efficiency (t(47) = 1.14, p = 0.26) were 
comparable between methods of measurement. This may have been, in part, because 
middle of the night awakenings may not be recalled as easily in the morning. However, 
this may also be a result of movement due to RLS, PLMD, or even sleep apnea that is 
interpreted as an awakening but not perceived by the participant. These movements may 
be indicative of partial arousals and disrupted sleep that are not considered full 
awakenings and therefore are not recalled or recorded in sleep diaries. 
Table 7.  
Sample Statistics 
Sleep Measures Mean (Standard Deviation) Range 
Insomnia Severity Index 11.58 (6.32) 1 - 25 
STOP-BANG 2.12 (1.40) 0 - 6 
Epworth Sleepiness Scale 9.16 (4.35)          3 - 20 
GSAQ Total 8.82 (6.03)          1 - 28 
GSAQ: RLS/PLMD 1.12 (1.5) 0 - 6 
PSQI total 8.02 (3.40) 2 - 14 
 
Sleep Continuity Variable Mean (Standard Deviation) Range 
	   28	  
Sleep Diary TST 7.10 (1.33) 4.34 –10.47 
Actigraphy TST 7.42 (1.26) 4.99 –11.68 
Sleep Diary SE% 85.96 (8.89) 60.00 – 98.00 
Actigraphy SE% 83.86 (5.53) 67.65 – 93.18 
Sleep Diary SOL 29.88 (27.57) 1.36 –134.29 
Actigraphy SOL 25.21 (13.60) 1.32 – 57.04 
Sleep Diary WASO 21.70 (23.10) 0.00-135.00 
Actigraphy WASO 46.20 (23.26) 12.89 – 156.43 
Sleep Diary Nap min/day 25.08 (31.23) 0 – 139.29 	  
Actigraphy Nap min/day 22.51 (42.98) 0 – 263.97 
 
Cognitive Measure Mean (Standard Deviation) Range 
PVT correct 101.91 (16.39) 54 – 121 
SRT Delayed Recall 8.45 (2.55) 3 – 12 
SDMT 51.63 (11.40) 31 – 77 
PASAT 3  43.10 (12.55) 18 – 60 
PASAT 2 31.69 (11.84) 10 – 54 
N-Back (1-back) 47.30 (3.00) 40 – 50 
N-Back (2-back) 37.37 (9.070) 15 – 52 
Working Memory Composite* 72.85 (15.05) 29 – 95 
UFOV Divided Attention 33.38 (41.60) 14 – 184 
DKEFS Set-Shifting 26.11 (11.98) 7 – 68 
DKEFS Motor Speed 80.43 (33.99) 31 – 195 
COWAT 40.90 (11.79) 12 – 66 
Animals 21.85 (5.63) 11 – 37 
MRR (Pa-Ta-Ka) 1.57 (0.51) 0.70 – 3.00 
WASI Vocab T-score 51.42 (8.65) 34  – 73 
NART 110.71 (7.39) 98 – 128 
Note. *Working memory composite score is an average for the N-Back 1, N-Back 2, PASAT 2 and PASAT 
3 percent correct. 
 
Associations with sleep disorder symptomatology. Correlations between 
symptoms of sleep disorder and mood, fatigue, and sleepiness are reported in Table 8. 
Results of correlational analyses indicate a large correlation between insomnia severity 
and depression symptoms (BDI-FS), a moderate to large correlation between insomnia 
and sleep efficiency (sleep diary and actigraphy SE), trait anxiety (STAI-T), state 
sleepiness at the end of the testing session (SSS), and fatigue severity (FSS). 
Interestingly, insomnia severity was not associated with TST, age, or daytime sleepiness 
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(ESS). Sleep apnea was moderately associated with degree of daytime sleepiness (ESS) 
and age. RLS and PLMD were associated with fatigue severity (FSS) and state sleepiness 
(SSS) at the end of the testing session. 
 
Correlations between age, mood, and cognitive function. Correlations were used 
to examine the effects of age, education, and mood on dependent variables to identify 
potential covariates. In addition, the effect of medication use on cognitive function was 
examined to determine the need to co-vary for stimulant and/or sleep medicine use. The 
effect stimulant use on cognitive performance was examined using an independent t-test. 
Participants were asked to refrain from caffeine use at least four hours before the testing 
appointment and caffeine consumption was recorded. Participants were coded based on 
Table 8.  Associations with sleep disorder symptomatology 
 Insomnia (ISI) 
n = 17 
Sleep Apnea (STOP-BANG) 
n = 20 
RLS/PLMD (GSAQ) 
n = 29 
No sleep disorder 
n = 11 
Sleep Diary TST (r) 
M(SD) 
-.08 
6.75 (1.64) 
.00 
7.58 (1.32) 
.13 
7.37 (1.17) 
 
6.66 (0.61) 
Actigraphy TST (r) 
M(SD) 
.04 
7.51 (1.37) 
.24 
7.66 (1.48) 
.05 
7.52 (1.16) 
 
7.05 (0.85) 
Sleep Diary SE (r) 
M(SD) 
-.40* 
79.2 (10.07) 
.10 
84.89 (6.62) 
.01 
85.30 (9.99) 
 
88.18 (7.53) 
Actigraphy SE (r) 
M(SD) 
-.39* 
81.16 (6.28) 
-.06 
82.86 (6.32) 
-.13 
83.70 (6.20) 
 
85.28 (3.68) 
BDI-FS (r) 
M(SD) 
.61* 
5.12 (3.48) 
.16 
3.32 (2.87) 
.25 
2.69 (3.03) 
 
1.36 (1.80) 
STAI-T (r) 
M(SD) 
.33* 
38.75 (9.15) 
-.04 
35.78 (7.74) 
.23 
37.11 (8.49) 
 
31.50 (10.16) 
Sleepiness (ESS) (r) 
M(SD) 
-.05 
10.24 (5.07) 
.42* 
11.11 (4.38) 
.18 
9.28 (4.58) 
 
8.30 (3.77) 
Fatigue (FSS) (r) 
M(SD) 
.38* 
48.60 (12.46) 
.18 
46.94 (10.34) 
.33* 
46.00 (12.59) 
 
42.36 (8.66) 
Age (r) 
M(SD) 
-.05 
41.82 (9.26) 
.40* 
47.25 (5.76) 
.18 
44.97 (7.38) 
 
43.45 (5.30) 
State Sleepiness (SSS) (r) 
M(SD) 
.38* 
3.94 (1.81) 
.15 
3.78 (1.80) 
.32* 
3.56 (1.87) 
 
2.56 (1.13) 
State Fatigue (VASF) (r) 
M(SD) 
-.12 
5.18 (2.40) 
-.19 
4.89 (2.52) 
-.15 
5.48 (2.46) 
 
5.44 (2.24) 
Disability Status (EDSS) (r) 
M(SD) 
.34* 
4.62 (1.51) 
.30* 
4.35 (2.00) 
.24 
3.56 (1.74) 
 
2.36 (1.61) 
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whether they had taken a stimulant on the day of testing (n = 11), including caffeine or 
medication, within two hours of the appointment time or stimulant medication that day. 
Stimulant use was not associated with better performance on any tests of cognitive 
function and therefore was not used as a covariate in subsequent analyses (p >.05). 
Participants were not excluded for sleep medication use. However, participants reporting 
significant insomnia symptoms (ISI >14) were more likely to use sleep medication, than 
participants who were below the clinical/moderate threshold. Given the high frequency of 
sleep medication use, analyses examining the effect of insomnia symptoms on cognitive 
function will control for sleep medication use. Furthermore, due to the impact of manual 
and oral motor speed on test performance, tests that require timed verbal (COWAT, 
Animals, SDMT) or manual output (DKEFS set-shifting) will control for oral motor 
speed uing the MRR and manual motor speed using the 9-hole test, respectively. 
Depression was significantly correlated with PVT performance. Analyses using PVT will 
control for severity of depression. The results are reported with and without controlling 
for analyses including insomnia severity, given the high correlation between insomnia 
and depression (r = 0.61). Likewise, age was significantly correlated with the Stroop 
interference score. Analyses using Stroop interference will control for age. Results will 
be reported with and without controlling for age for analyses looking at the relationship 
between Stroop interface and STOP BANG, given that age contributes to the STOP 
BANG score.  
 
 
Table 9.  
Correlations Between Self-Report and Neurocognitive Measures 
	   31	  
 PVT SRT Delay SDMT 
UFOV 
Divided  
Attention 
DKEFS 
set-shifting 
 
COWAT 
 
ANIMAL 
Working 
memory Stroop Interference 
Age -.19 -.32* -.19 .26 .18 -.15 
 
-.24 
 
-.25 -.33* 
BDI-fs -.32* -.02 -.15 .11 .25 -.23 
 
-.17 
 
-.11 -.14 
STAI: State -.06 -.01 .05 .04 .21 -.14 
 
-.19 
 
.07 -.09 
STAI: Trait -.13 -.06 -.19 .20 .03 -.27 
 
-.31* 
 
-.10 -.29* 
Note. *Correlation is significant at the 0.05 level (2-tailed). 
**Correlation is significant at the 0.01 level (2-tailed). 
 
Primary Analyses 
To reduce the chance of a type 1 error, significance will be determined if 
significance level is below .01 for all analyses under the primary aim.  
Aim 1a. To test whether self-reported sleep quality, as measured by the PSQI, 
predicted performance on measures of processing speed, attention, vigilance, working 
memory, mental flexibility and inhibitory control multiple linear regressions were 
examined. Analyses controlled for age and mood as described above. Results indicate 
that sleep quality measured by the PSQI was not associated with psychomotor vigilance, 
processing speed, attention, working memory, mental flexibility, or inhibitory control 
(see Table 9). Of note, sleep quality was associated with psychomotor vigilance without 
controlling for depression (p < .01, r  = -.40). This suggests that depression may mediate 
the relationship between sleep quality and psychomotor vigilance. 
 
 
 
Table 10.  
Sleep Quality and Cognitive Function 
PSQI Total Score   
T 
 
F 
 
df 
 
p 
(Partial) 
Correlation r 
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β 
Processing Speed 
        SDMT 
 
.05 
 
.36 
 
.89 
 
3,46 
 
.72 
 
.05 
Attention 
UFOV Divided attention 
 
.17 
 
-1.18 
 
1.74 
 
1,49 
 
.24 
 
.17 
Psychomotor Vigilance Test 
PVT 
 
-.27 
 
-2.03 
 
8.53 
 
2,44 
 
.05 
 
-.26 
Working Memory 
WM Composite 
 
-.12 
 
-.87 
 
.75 
 
1,49 
 
.39 
 
-.12 
Mental Flexibility 
DKEFS switching 
 
.06 
 
.39 
 
.13 
 
2,49 
 
.70 
 
.06 
Inhibition 
Stroop Interference 
 
-.05 
 
-.54 
 
3.78 
 
3,45 
 
.50 
 
-.08 
Memory 
  SRT Delay 
 
.15 
 
1.01 
 
1.15 
 
2,48 
 
.32 
 
.14 
Verbal Fluency 
COWAT 
Animals 
 
-.05 
.07 
 
-.35 
.47 
 
1.20 
3.50 
 
2,47 
3,43 
 
.73 
.64 
 
-.05 
.07 
 
Aim 1b. Multiple linear regressions were used to examine whether (1) total sleep 
time and (2) sleep efficiency measured by a (a) sleep diary (b) accelerometer predict 
performance on measures of processing speed, attention, vigilance, working memory, 
mental flexibility, and inhibitory control. Analyses controlled for age and mood as 
described above. Sleep continuity variables taken from sleep diaries and actigraphy were 
not associated with cognitive performance in this sample (see tables 10-13).  
Table 11.  
Sleep Diary Total Sleep Time and Cognitive Function 
TST sleep diary  
Β 
 
t 
 
F 
 
df 
 
p 
(Partial) 
Correlation r 
Processing Speed 
        SDMT 
 
-.18 
 
-1.23 
 
2.25 
 
3,45 
 
.22 
 
.18 
Attention 
UFOV Divided 
 
.01 
 
.09 
 
.01 
 
1,48 
 
.91 
 
.02 
Psychomotor Vigilance 
Test 
PVT 
 
.10 
 
.09 
 
1.19 
 
2,43 
 
.93 
 
.01 
Working Memory 
WM Composite 
 
-.04 
 
7.78 
 
.07 
 
1,48 
 
.79 
 
-.04 
Mental Flexibility 
DKEFS switching 
 
.18 
 
1.16 
 
1.22 
 
2,47 
 
.60 
 
.17 
Inhibition 
Stroop Interference 
 
.02 
 
.13 
 
1.18 
 
3,44 
 
.90 
 
.19 
Memory 
  SRT Delay 
 
.23 
 
1.52 
 
3.08 
 
2,47 
 
.14 
 
.22 
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Verbal Fluency 
COWAT 
Animals 
 
-.31 
.09 
 
-2.30 
-3.40 
 
5.21 
1.68 
 
2,46 
3,42 
 
.03 
.56 
 
-.32 
.09 
 
Table 12.  
Actigraphy Total Sleep Time and Cognitive Function 
TST actigraphy  
Β 
 
t 
 
F 
 
df 
 
p 
(Partial) 
Correlation r 
Processing Speed 
        SDMT 
 
.02 
 
-.30 
 
.52 
 
3,45 
 
.77 
 
.05 
Attention 
UFOV Divided 
 
.10 
 
.70 
 
.21 
 
1,48 
 
.65 
 
.07 
Psychomotor Vigilance 
Test 
PVT 
 
.01 
 
1.0 
 
.57 
 
2,43 
 
.35 
 
.14 
Working Memory 
WM Composite 
 
.00 
 
-.02 
 
.00 
 
1.48 
 
.99 
 
.00 
Mental Flexibility 
DKEFS switching 
 
.17 
 
.59 
 
.59 
 
2,47 
 
.28 
 
.16 
Inhibition 
Stroop Interference 
 
.04 
 
.25 
 
.90 
 
3,44 
 
.80 
 
.04 
Memory 
  SRT Delay 
 
.24 
 
1.57 
 
2.25 
 
2,47 
 
.12 
 
.22 
Verbal Fluency 
COWAT 
Animals 
 
-.10 
.00 
 
-.70 
.07 
 
.70 
.43 
 
2,46 
3,42 
 
.49 
.95 
 
-.10 
.01 
  
Table 13.  
Sleep Diary Sleep Efficiency and Cognitive Function 
SE sleep diary  
Β 
 
T 
 
F 
 
df 
 
P 
(Partial) 
Correlation r 
Processing Speed 
        SDMT 
 
.01 
 
.08 
 
2.01 
 
3,43 
 
.94 
 
.01 
Attention 
UFOV Divided 
 
.15 
 
1.00 
 
1.02 
 
1,46 
 
.32 
 
-.15 
Psychomotor Vigilance 
Test 
PVT 
 
.00 
 
-.26 
 
2.24 
 
2,41 
 
.80 
 
-.04 
Working Memory 
WM Composite 
 
.18 
 
1.27 
 
1.61 
 
1,46 
 
.21 
 
.18 
Mental Flexibility 
DKEFS switching 
 
.14 
 
.90 
 
.58 
 
2,45 
 
.37 
 
.13 
Inhibition 
Stroop Interference 
 
.30 
 
1.81 
 
1.77 
 
3,42 
 
.08 
 
.27 
Memory 
  SRT Delay 
 
.06 
 
.35 
 
.54 
 
2,45 
 
.73 
 
.05 
Verbal Fluency 
COWAT 
Animals 
 
-.16 
.09 
 
-1.14 
.57 
 
3.33 
2.28 
 
2,44 
3,40 
 
.26 
.57 
 
-.17 
.09 
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Table 14.  
Actigraphy Sleep Efficiency and Cognitive Function 
SE Actigraphy  
β 
 
T 
 
F 
 
df 
 
p 
(Partial) 
Correlation r 
Processing Speed 
        SDMT 
 
-.06 
 
-.42 
 
.68 
 
3,45 
 
.68 
 
-.06 
Attention 
UFOV Divided 
 
.07 
 
.47 
 
.29 
 
1,48 
 
.64 
 
.07 
Psychomotor Vigilance Test  
PVT 
 
.01 
 
.28 
 
2.53 
 
2,43 
 
.78 
 
.04 
Working Memory 
WM Composite 
 
.20 
 
1.38 
 
1.89 
 
1,48 
 
.18 
 
.20 
Mental Flexibility 
DKEFS switching 
 
.20 
 
1.32 
 
.20 
 
2,47 
 
.19 
 
.09 
Inhibition 
Stroop Interference 
 
.04 
 
.25 
 
.89 
 
3,44 
 
.80 
 
.04 
Memory 
  SRT Delay 
 
-.03 
 
-.18 
 
1.09 
 
2,47 
 
.86 
 
-.03 
Verbal Fluency 
COWAT 
Animals 
 
.08 
.08 
 
.58 
.52 
 
.99 
.99 
 
2,46 
3,42 
 
.56 
.61 
 
.09 
.08 
 
Aim 2. Correlations were used obtain estimates of effect size for the relationships 
between symptoms of specific sleep disorders and cognitive function: (a) Insomnia 
Severity Index total score and measures of attention, vigilance, verbal memory, and 
working memory; (b) Risk for sleep apnea as measured with attention, vigilance, verbal 
fluency, memory, working memory, inhibition, and processing speed; (c) RLS and 
PLDM symptom severity on measures of executive functioning (i.e., attention, working 
memory, mental flexibility, inhibitory control, and verbal fluency). Given that this aim is 
exploratory, significance will be interpreted at p < .05. 
Table 15.  
Insomnia Severity and Cognitive Function 
ISI R p 
Attention 
UFOV Divided Attention 
 
.27* 
 
.03 
Vigilance 
PVT 
 
-.32* 
 
.02 
Working Memory 
WM Composite 
 
-.33* 
 
 
.01 
Verbal Memory 
SRT Delay 
 
-.09 
 
.28 
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Mental Flexibility 
DKEFS switching 
 
.43* 
 
<.01 
Note. All analyses controlled for sleep medication use. 
 
Results suggest a moderately strong relationship between insomnia severity and 
attention, vigilance, working memory, and mental flexibility (see Table 14). In addition 
to co-varying for motor speed and age as described above, all analyses with insomnia 
severity controlled for sleep medication use. Of note, when controlling for depression, 
PVT and insomnia are no longer significantly correlated (r = -0.11, p = 0.24). As noted 
above, depression and insomnia are highly correlated (r = 0.61).  Insomnia severity was 
not associated with verbal memory. All relationships were in the expected direction. That 
is, insomnia severity was related with poorer performance on these measures.  
 
Table 16.  
Risk for Sleep Apnea and Cognitive Function 
 
 
 
 
 
 
 
 
 
 
 
Note. Nine-hole test examined an average of left and right hand manual dexterity 
 
STOP BANG R p 
Attention 
UFOV Divided Attention 
 
.20 
 
.17 
Working Memory 
WM Composite 
 
-.57* 
 
<.001 
Vigilance 
PVT 
 
-.44* 
 
<.01 
Inhibition 
Stroop Interference 
 
-.42* 
 
<.01 
Verbal Fluency 
COWAT 
Animals 
 
-.41* 
-.06 
 
<.01 
.34 
Verbal Memory 
SRT Delay 
 
.03 
 
.41 
Mental Flexibility 
DKEFS switching 
 
.33* 
 
.01 
Processing Speed 
SDMT 
 
-.42* 
 
<.01 
Psychomotor Speed 
Nine Hole Test average 
Timed walking Test 
 
.34* 
.13 
 
.02 
.39 
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Correlation analyses indicate a moderately strong, significant, relationship 
between risk for sleep apnea and vigilance, working memory, inhibition, verbal fluency, 
mental flexibility, processing speed, and psychomotor speed and a small to moderate 
correlation with divided attention (see Table 15). There was little or no relationship 
between risk for sleep apnea and memory, semantic fluency, or timed walking speed. All 
relationships were in the expected direction. That is, risk for sleep apnea was related with 
poorer performance on these measures. 
Table 17.  
RLS/PLMD and cognitive function 
RLS/PLMD GSAQ R p 
Attention 
UFOV Divided Attention 
 
.52* 
 
<01 
Working Memory  
WM Composite 
 
-.29* 
 
<.01 
Inhibition 
Stroop Interference 
 
-.02 
 
.15 
Mental Flexibility 
DKEFS switching 
 
.11 
 
.22 
Verbal Fluency 
COWAT 
Animals 
 
-10 
-.01 
 
.25 
.49 
 
Correlation analyses indicate a large effect size in the relationship between RLS 
and PLMD symptoms and divided attention and a small to moderate correlation with 
working memory (see Table 16). The statistics reported above for the relationship 
between inhibitory control and movement-related sleep disorders are controlling for age 
and trait anxiety. When these variables are not controlled for, the relationship becomes 
significant (r = -.27, p = .03). Symptoms of RLS and PLMD were not substantially 
related to other measures of executive function and verbal fluency employed in this 
study. All relationships were in the expected direction. That is, severity of sleep disorder 
symptomology was related with poorer performance on these measures. 
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CHAPTER 4: DISCUSSION  
The aim of this study was to examine the relationship between sleep and cognitive 
function in individuals with relapsing-remitting MS. Self-report and objectively measured 
sleep parameters revealed a range of sleep duration and efficiency in this sample. Sleep 
quality was poor for the majority of participants. Likewise, the majority of participants 
screened positive for symptoms of sleep disorders. The key findings of this study 
indicated that symptoms of sleep disorders were generally associated with poorer 
cognitive function. However, there was no significant pattern of association between 
sleep duration, efficiency MS, it is important to describe the range of sleep quality and 
quantity in this population., or sleep quality and cognitive function. 
Sleep in relapsing-remitting MS 
In order to understand the relationship between sleep and cognitive function in 
Average sleep duration for this sample was consistent with sleep duration reported in the 
general adult population in the United States, between 7 to 8 hours per night (Singh et al., 
2005), and average sleep efficiency was good (85%).  However, there was a wide range 
of reported sleep duration (4.5 to 10 hours per night) and sleep efficiency (60% to 98%). 
Over half of the sample was considered “poor sleepers” according to the PSQI. Many of 
the common causes of sleep disturbances were related to symptoms of MS, including 
urinary frequency, pain, and muscle cramps or spasms. Many also reported that “worry” 
impacted their sleep quality. Daytime sleep, sleepiness, and fatigue were also prevalent in 
this sample. Fatigue is one of the most common symptoms reported in MS, and 71% of 
the sample reported significant fatigue. A large percentage (42%) also reported 
significant daytime sleepiness at a level that suggests clinical assessment is indicated. 
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Most participants (87%) reported napping at least once during the two-week sleep-
monitoring period, and on average, participants spent 25 minutes napping or dozing per 
day. While seven participants did not nap at all, one participant spent up to 4 hours a day 
napping. Overall, the results of this study indicate that there is a wide range of variability 
in sleep in MS, with a large percentage of individuals experiencing poor sleep quality, 
significant daytime sleepiness, and fatigue. 
Convergence between objective and subjective measures of sleep duration and 
efficiency was large, consistent with past research. Previous studies have found that 
actigraphy may underestimate sleep duration in individuals with insomnia due to long 
periods of time lying still while sleeping. In this sample, sleep duration and WASO were 
significantly different between actigraphy and sleep diary measurements. Furthermore, 
these measures were more strongly correlated for participants who did not screen positive 
for insomnia. This may be a result of the actigraphy measuring sleep time in individuals 
with insomnia who are lying still, awake in bed. In addition, individuals with insomnia 
tend to perceive that they are spending more time awake in bed. Although both measures 
tend to underestimate sleep duration and efficiency compared to polysomnography, 
actigraphy is considered to be a more accurate measure of these variables (Vallieres, 
2003). 
As for symptoms of sleep disorders, the majority of the participants in this sample 
screened positive for one or more sleep disorders, including insomnia (34%), sleep apnea 
(39%), RLS (35%), and PLMD (41%). These rates are very high compared to the general 
population, but consistent with previous research in MS. Brass and colleagues reported 
comparable rates of insomnia at 32%, sleep apnea at 38%, and RLS at 37%. The 
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prevalence of these disorders is substantially higher in MS than in the general adult 
population. In the current study, insomnia rates were over three times higher, sleep apnea 
was screened at three to four times higher, RLS between two to twelve times higher, and 
PLMD was ten times higher than what has been reported in the general population. 
Moreover, although 77% screened positive for sleep disorder, only 25% of the sample 
reported having a diagnosed sleep disorder, including insomnia (2%), sleep apnea (9%), 
and RLS (9%). This is a considerable discrepancy between diagnosis and presence of 
clinically significant symptoms. Despite a low rate of diagnosed sleep disorders, a 
majority of the sample (84%) reported taking prescription over the counter medications 
for sleep sometime in the past month, much higher than what has been reported in the 
general U.S. population (11% use prescription medication and 4% using over the counter 
medication) (Morin et al., 2006). The high rate of sleep medication use illustrates that 
individuals with MS are turning to medicine for help with their sleep problems, yet many 
have not been formally diagnosed with a sleep disorder. This may be problematic if these 
individuals are not getting the clinically appropriate treatment for their sleep concerns. 
Sleep disorders are highly treatable, but proper assessment and diagnosis is important for 
optimal treatment, given that the appropriate treatment can vary greatly for different sleep 
disorders.   
Sleep Duration, Efficiency, Quality and Cognitive Function 
In regards to the primary hypothesis, our findings did not reveal any significant 
relationships between sleep duration or efficiency and cognitive function. Poorer sleep 
quality, was associated with reduced psychomotor vigilance, but this relationship did not 
persist when controlling for depression. The absence of significant findings in the 
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primary hypotheses may be due to key differences in the methodology of this study 
compared with the current literature investigating sleep and cognitive function in 
medically healthy adults. First, previous research on sleep and cognitive function has 
typically excluded for the presence of sleep disorders, but the majority of the present 
sample screened positive for one or more sleep disorder. This is crucial since sleep 
disorders can differentially impact sleep duration and sleep efficiency. For example, as 
outlined in Table 8, on average, sleep duration was lowest for individuals with no sleep 
disorder (6.66 hours), followed by those with insomnia, then movement-related sleep 
disorders, and was highest for sleep apnea (7.58 Hours). Sleep efficiency was lowest in 
insomnia (79%), followed by sleep apnea, movement-related sleep disorders, and was 
highest in those with no sleep disorder (88%). Of note, these differences were not tested 
statistically because the groups are not considered independent, with participants 
included in multiple sleep disorder groups. However, qualitative observation of these 
differences, suggests that sleep duration and efficiency may not be reliable predictors of 
cognitive function in a sample of individuals with heterogeneous sleep disorder 
symptomology because sleep disorders impact cognitive function, sleep duration, and 
sleep efficiency in different and systematic ways. Sleep quality, as measured in this 
study, is largely based on participant report of sleep duration and efficacy, and therefore 
may be sensitive to the same limitations as sleep duration and efficiency in this 
population.  
In addition, the consensus literature defining the relationship between sleep 
duration and cognitive function is primarily based on research that has experimentally 
controlled for sleep duration in overnight sleep studies, as opposed to the prospective, 
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naturalistic method of data collection used in the present study. The method for data 
collection using in this study is particularly useful for gaining clinically relevant 
information on normative sleep behavior in MS. However, a naturalistic method of 
measuring sleep allows for less control over the influence of outside factors, such as 
mood, age, neuropsychological impairment, location of white matter lesions, physical 
disability, employment status, daytime sleep, medication use, etc., which can all create 
noise in the ability to detect a relationship between sleep duration or efficiency and 
cognitive function. We attempted to reduce potential noise by controlling for relevant 
factors statistically, but these highly complex interactions can be difficult to control 
without experimental methods. This study chose to examine naturalistic measures of 
sleep with the aim of identifying targets for intervention that may improve cognitive 
function. These results suggests that sleep duration and efficiency may not be particularly 
useful measures to address the effects of sleep on cognitive function in MS based on the 
high prevalence and heterogeneity of sleep disorder in this population. Furthermore, it is 
not clinically indicated to alter sleep duration or efficiency in the absence of a clinical 
syndrome, and there are no treatments designed for this purpose. Rather, focusing on the 
impact of sleep disorders on cognitive function may be a more meaningful approach to 
identifying targets for intervention. 
Sleep Disorders Symptoms and Cognitive Function 
The key findings of this study indicate that symptoms of sleep disorders are 
associated with poorer cognitive function. Insomnia was associated with decrements in 
attention, vigilance, working memory, and mental flexibility.  Risk for sleep apnea was 
associated with decreased vigilance, working memory, inhibition, verbal fluency, mental 
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flexibility, processing speed, psychomotor speed, and divided attention. RLS and PLMD 
symptoms were associated with poorer divided attention and working memory.  These 
findings are consistent with previous research looking at the relationship between 
symptoms of sleep disorders and cognitive function in neurologically healthy samples, 
with the following exceptions: (1) this study did not find a significant association 
between insomnia and verbal memory (2) risk for sleep apnea was no associated with 
verbal memory or semantic fluency, and (3) symptoms of RLS and PLMD were not 
significantly related to verbal fluency, inhibition, or mental flexibility.  
About 45–65% of persons with MS experience cognitive impairments (Rao, Leo, 
Bernardin, et al., 1991), most often in the domains of processing speed, attention, and 
executive functioning (Rao, Leo, Bernardin, et al., 1991). There is a consistent pattern of 
deficits in disorders attention and executive function associated with sleep in this sample, 
two domains of cognitive function that are often impacted in MS. The results of this 
study suggest that a sleep disorder may increase risk and/or severity of cognitive 
impairment in a population that is inherently vulnerable to cognitive decline. This is 
important because even mild impairments in cognitive function can significantly interfere 
with a person’s ability to complete activities of daily living, (e.g., personal care and 
driving), function socially, and meet occupational demands (Rao, Leo, Ellington, et al., 
1991; Ruet et al., 2013; Schultheis et al., 2001). Therefore, improving cognitive function 
would likely improve quality of life and independence for individuals with MS. 
Treatment of sleep disorders may be a useful target for intervention in improving 
cognitive function in this population given the high prevalence of sleep disorders in MS.  
Strengths and Limitations 
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 This study has several important strengths and novel contributions.  For one, 
multiple methods for sampling sleep and cognitive function in MS were used. The use of 
both subjective (i.e., sleep diary and PSQI) and objective (i.e., actigraphy) prospective 
measurements of sleep over 14 consecutive days was another important strength in this 
study. Furthermore, no previous studies have looked at actigraphy recorded sleep and 
cognitive function in MS. Previous studies have relied on self-reported retrospective 
estimates of sleep duration, which tends to be less accurate than the measures used in this 
study. Although there was a high correlation between sleep diary and actigraphy, these 
measures were not perfectly correlated, and therefore contribute unique information 
about sleep behavior.  Likewise, this was the first study to look at the association between 
symptoms of sleep disorders and cognitive function in MS. The use of both quantitative 
measures of sleep (duration and efficiency) and assessment of symptoms of sleep 
disorders allowed for the comparison of the utility of these indices for predicting 
cognitive function. In addition to a comprehensive assessment of sleep, this study 
incorporated a wide range of neurocognitive measures sensitive to the effects of sleep 
disorders and shortened sleep duration. Finally, measurement of many potential 
covariates, including age, mood, manual motor speed, oral motor speed, and stimulant 
use was another strength of this study. 
One important limitation was the need to rely on questionnaires to assess 
symptoms of sleep disorders. Diagnosis of a sleep disorder requires clinical assessment 
and, in some cases, an overnight sleep study. Furthermore, the questionnaires used in this 
study have not been validated in MS. Additional research is needed to determine whether 
the sensitivity or specificity of these measures is impacted in MS specific symptoms. For 
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example, measures screening for RLS may have a high false-positive rate due to 
paresthesia, cramps, and muscle spasms in MS that may not fit the clinical syndrome of 
RLS (Mery et al., 2015). Likewise, actigraphy and sleep diaries have been well validated 
in samples of medically healthy adults with no sleep disorders, but have not been 
validated in MS. These results should be interpreted with caution given that there is 
evidence that actigraphy and sleep diary are less reliable in certain populations. For 
example, actigraphy tends to over-estimate sleep duration and efficiency in insomnia, due 
to the tendency for people with insomnia to lie awake in bed motionless (Sadeh, 2011). 
Sleep diaries may also be more susceptible to error in certain populations, such as older 
adults with cognitive impairments and significant functional disability and adults with 
depressed mood (McCall & McCall, 2012). However, measuring sleep for seven or more 
days typically improves the reliability of these measurements to an acceptable level (Van 
Someren, 2007).    
The correlational and cross-sectional design of this study is an inherent limitation. 
As described above, experimental methods may be helpful to best understand the 
relationship between sleep duration and cognitive function in individuals with MS who 
do not meet criteria for a sleep disorder.  Experimental methods may also help to control 
for potential circadian effects on cognitive function by restricting or controlling for time 
of day in which participants complete cognitive measures. In addition, experimental 
research investigating changes in cognitive function associated with treatment of sleep 
disorders is warranted. 
The proposed sample size was based on findings in a previous study employing a 
similar sample and some of the same measures of cognitive function. Sleep quality and 
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duration in the reference study were measured using subjective and retrospective indices 
of sleep. The reference study appears to have had larger effect sizes for sleep quality and 
duration than found in this study. The power analysis suggested a sample of 77 
participants. A larger sample may have allowed for additional significant relationships to 
emerge.  
Finally, the absence of a matched-control group of neurologically healthy adults 
limits the ability to draw conclusions about the unique relationship between sleep and 
cognitive function in MS. As a result, we must rely on the existent literature describing 
the relationship between sleep and cognitive function in medically healthy adults. 
Although there are many studies looking at the relationship between sleep duration and 
sleep disorder symptoms and cognitive function in neurologically health adults, this is not 
the ideal comparison group due to differences in methodology compared to the current 
study.  
Future Directions 
 First, future studies are needed to replicate the extant findings in individuals with 
MS with clinically confirmed sleep disorder diagnoses. Using clinical assessment and 
polysomnography to confirm sleep disorder diagnosis would also allow for examination 
of these relationships in other sleep disorders, such as narcolepsy and REM behavior 
disorder, which have low base-rates and has do not have a well-validated screening 
questionnaires. 
 Second, additional research is needed to better understand the nature of the 
relationship between sleep and cognitive function in MS. For example, it would be useful 
to examine the relationship between sleep duration and efficiency and cognitive function 
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separately within specific sleep disorders, or within those who did not screen positive for 
a sleep disorder. Likewise, follow-up analyses may help to identify possible role of 
cognitive reserve, sleep medication use, or disease severity in moderating the impact of 
symptoms of sleep disorders. The current study lacks sufficient power to adequately 
explore these future directions. Furthermore, in order to better understand how sleep and 
sleep disorders may uniquely impact individuals with MS, future studies may include a 
neurologically healthy matched-control group. A control group would need to be matched 
on symptoms of sleep disorders, age, education, and gender.  
Third, a majority of the participants in this sample screened positive for sleep 
disorders. Consistent with past research in MS, most participants who screen positive for 
sleep disorders did not have a diagnosed sleep disorder (Brass et al., 2014). This is 
concerning given the serious consequences of untreated sleep disorders on one’s physical 
health, quality of life, and mortality (Kendzerska et al., 2014; Loke et al., 2012; Reimer 
& Flemons, 2003; Thomas Roth & Roehrs, 2003). Untreated sleep apnea should be of 
particular concern in a neurodegenerative disease, such as MS, because it can lead to grey 
and white matter volume loss and systematic inflammation (Chen et al., 2015; Weng et 
al., 2014). The current literature suggests that there may be a high rate of undiagnosed 
sleep disorders in MS. Therefore, additional research and education is needed to improve 
assessment, diagnosis, and treatment of sleep disorder in this population. In addition, this 
study suggests that physicians working with patients with MS should regularly screen 
patients for symptoms of sleep disorders. 
 Fourth, in addition to improving assessment, diagnosis, and treatment of sleep 
disorders, future research is needed to examine whether treatment of sleep disorders can 
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improve cognitive function in individuals with MS. Sleep disorders and cognitive 
dysfunction are both associated with decreased quality of life. If sleep disorders are 
exacerbating cognitive difficulties in MS, treatment of sleep disorders may alleviate 
cognitive dysfunction in this population For example, there is evidence that treatment of 
sleep apnea can ameliorate the sleep-dependent cognitive deficits (for review see Aloia, 
et al., 2004) and reverse grey and white matter volume loss (Canessa et al., 2011; 
Castronovo et al., 2014). Less is known about the potential for improving cognitive 
function through treatment of other sleep disorders, such as insomnia, RLS, or PLMD. 
No studies, to date, have looked at the potential for improving cognitive function in MS 
through treatment of sleep disorders. Treatment of insomnia and sleep apnea can alleviate 
symptoms of depression (Ejaz, Khawaja, Bhatia, & Hurwitz, 2011 for review; Manber, et 
al., 2008; Wagley, et al., 2013). This is important given the high prevalence of depression 
in MS and the unique impact depression can have on cognitive function. This is an 
important area for future research give than sleep disorders are highly treatable and may 
serve as a modifiable risk factor for cognitive impairment in MS. 
Conclusion 
This study set out to examine the relationship between sleep and cognitive 
function in individuals with relapsing-remitting MS. The results revealed a high 
frequency of poor sleep quality and sleep disorders in this population. Although there was 
no significant pattern of association between sleep duration, efficiency, or sleep quality 
and cognitive function, symptoms of sleep disorders were associated with poorer 
cognitive function. This study underscores the importance of, and the need for, additional 
research on sleep and sleep disorders in MS. More importantly, these findings emphasize 
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the need for research aimed at improving clinical assessment, diagnosis, and treatment of 
sleep disorder in this population. 
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Appendix A: Sleep diaries 
Consensus Sleep Diary   
(modified from Carney, et al., 2012) 
Morning Sleep Diary Item Instructions 
Use the guide below to clarify what is being asked for each item of the Sleep Diary. Date: Write 
the date of the morning you are filling out the diary. 
1. What time did you get into bed? Write the time that you got into bed. This may not be the time 
you began “trying” to fall asleep. 
2. What time did you try to go to sleep? Record the time that you began “trying” to fall asleep. 3. 
How long did it take you to fall asleep? Beginning at the time you wrote in question 2, how long 
did it take you to fall asleep. 
4. How many times did you wake up, not counting your final awakening? How many times did 
you wake up between the time you first fell asleep and your final awakening? 
5. In total, how long did these awakenings last? What was the total time you were awake between 
the time you first fell asleep and your final awakening. For example, if you woke 3 times for 20 
minutes, 35 minutes, and 15 minutes, add them all up (20+35+15= 70 min or 1 hr and 10 min). 
6a. What time was your final awakening? Record the last time you woke up in the morning. 
6b. After your final awakening, how long did you spend in bed trying to sleep? After the last time 
you woke-up (Item #6a), how many minutes did you spend in bed trying to sleep? For example, if 
you woke up at 8 am but continued to try and sleep until 9 am, record 1 hour. 6c. Did you wake 
up earlier than you planned? If you woke up or were awakened earlier than you planned, check 
yes. If you woke up at your planned time, check no. 
6d. If yes, how much earlier? If you answered “yes” to question 6c, write the number of minutes 
you woke up earlier than you had planned on waking up. For example, if you woke up 15 minutes 
before the alarm went off, record 15 minutes here. 
7. What time did you get out of bed for the day? What time did you get out of bed with no further 
attempt at sleeping? This may be different from your final awakening time (e.g. you may have 
woken up at 6:35 a.m. but did not get out of bed to start your day until 7:20 a.m.) 
8. In total, how long did you sleep? This should just be your best estimate, based on when you 
went to bed and woke up, how long it took you to fall asleep, and how long you were awake. You 
do not need to calculate this by adding and subtracting; just give your best estimate. 
9. How would you rate the quality of your sleep? “Sleep Quality” is your sense of whether your 
sleep was good or poor. 
10. How restful or refreshed did you feel when you woke up for the day? This refers to how you 
felt after you were done sleeping for the night, during the first few minutes that you were awake. 
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Nighttime Sleep Diary Item Instructions 
Please complete the following items before you go to bed. Date: Write the date of the evening 
you are filling out the diary. 
11a. How many times did you nap or doze? A nap is a time you decided to sleep during the day, 
whether in bed or not in bed. “Dozing” is a time you may have nodded off for a few minutes, 
without meaning to, such as while watching TV. Count all the times you napped or dozed at any 
time from when you first got out of bed in the morning until you got into bed again at night. 
11b. In total, how long did you nap or doze? Estimate the total amount of time you spent napping 
or dozing, in hours and minutes. For instance, if you napped twice, once for 30 minutes and once 
for 60 minutes, and dozed for 10 minutes, you would answer “1 hour 40 minutes.” If you did not 
nap or doze, write “N/A” (not applicable). 
12a. How many drinks containing alcohol did you have? Enter the number of alcoholic drinks 
you had where 1 drink is defined as one 12 oz beer (can), 5 oz wine, or 1.5 oz liquor (one shot). 
12b. What time was your last drink? If you had an alcoholic drink yesterday, enter the time of day 
in hours and minutes of your last drink. If you did not have a drink, write “N/A” (not applicable). 
13a. How many caffeinated drinks (coffee, tea, soda, energy drinks) did you have? Enter the 
! !
!
Morning form: Please complete upon awakening!!!
!
Today’s Date        
1. What time did you get 
into bed? 
 
 
      
2. What time did you try 
to go to sleep? 
 
 
      
3. How long did you take 
to fall asleep? 
 
 
      
4. How many times did 
you wake up, not counting 
your final awakening? 
       
5. In total, how long did 
these awakenings last? 
       
6a. What time was your 
final awakening? 
 
 
      
6b. After your final 
awakening, how long did 
you spend in bed trying to 
sleep? 
       
6c. Did you wake earlier 
than planned? 
 If yes, how much earlier? 
☐Yes ☐NO ☐Yes ☐NO ☐Yes ☐NO ☐Yes ☐NO ☐Yes ☐NO ☐Yes ☐NO ☐Yes ☐NO 
7. What time did you get 
out of bed for the day? 
       
8. In total, how long did 
you sleep? 
 
 
      
9. How would you rate 
your sleep? 
☐Very poor 
☐Poor 
☐Fair 
☐Good 
☐Very Good 
☐Very poor 
☐Poor 
☐Fair 
☐Good 
☐Very Good 
☐Very poor 
☐Poor 
☐Fair 
☐Good 
☐Very Good 
☐Very poor 
☐Poor 
☐Fair 
☐Good 
☐Very Good 
☐Very poor 
☐Poor 
☐Fair 
☐Good 
☐Very Good 
☐Very poor 
☐Poor 
☐Fair 
☐Good 
☐Very Good 
☐Very poor 
☐Poor 
☐Fair 
☐Good 
☐Very Good 
10. How rested or 
refreshed did you feel 
when you woke-up for the 
day? 
☐Not at all rested 
☐Slightly rested 
☐Somewhat rested 
☐Well-rested 
☐Very well-rested 
☐Not at all rested 
☐Slightly rested 
☐Somewhat rested 
☐Well-rested 
☐Very well-rested 
☐Not at all rested 
☐Slightly rested 
☐Somewhat rested 
☐Well-rested 
☐Very well-rested 
☐Not at all rested 
☐Slightly rested 
☐Somewhat rested 
☐Well-rested 
☐Very well-rested  
☐Not at all rested 
☐Slightly rested 
☐Somewhat rested 
☐Well-rested 
☐Very well-rested  
☐Not at all rested 
☐Slightly rested 
☐Somewhat rested 
☐Well-rested 
☐Very well-rested  
☐Not at all rested 
☐Slightly rested 
☐Somewhat rested 
☐Well-rested 
☐Very well-rested  
11. If you experienced any 
sleep disturbance last 
night, what would you 
attribute it to? (Check all 
that apply.) 
☐Bathroom needs 
☐Pain 
☐Muscle stiffness 
☐Spasms  
☐Worry 
☐Medication  
☐Other: 
☐Bathroom needs 
☐Pain 
☐Muscle stiffness 
☐Spasms  
☐Worry 
☐Medication  
☐Other:  
☐Bathroom needs 
☐Pain 
☐Muscle stiffness 
☐Spasms  
☐Worry 
☐Medication  
☐Other: 
☐Bathroom needs 
☐Pain 
☐Muscle stiffness 
☐Spasms  
☐Worry 
☐Medication  
☐Other:  
☐Bathroom needs 
☐Pain 
☐Muscle stiffness 
☐Spasms  
☐Worry 
☐Medication  
☐Other:  
☐Bathroom needs 
☐Pain 
☐Muscle stiffness 
☐Spasms  
☐Worry 
☐Medication  
☐Other:  
☐Bathroom needs 
☐Pain 
☐Muscle stiffness 
☐Spasms  
☐Worry 
☐Medication  
☐Other:  
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number of caffeinated drinks (coffee, tea, soda, energy drinks) you had where for coffee and tea, 
one drink = 6-8 oz; while for caffeinated soda one drink = 12 oz. 
13b. What time was your last drink? If you had a caffeinated drink, enter the time of day in hours 
and minutes of your last drink. If you did not have a caffeinated drink, write “N/A” (not 
applicable) 
14. Did you take any over-the-counter or prescription medication(s) to help you sleep? If so, list 
medication(s), dose, and time taken: List the medication name, how much and when you took 
EACH different medication you took tonight to help you sleep. Include medication available over 
the counter, prescription medications, and herbals (example: "Sleepwell 50 mg 11 pm"). If every 
night is the same, write “same” after the first day 
15. Did you take your accelerometer off today? If you took off your accelerometer at any point 
today, please note the time. Please note that you do not need to take the accelerometer off unless 
you were diving in greater than 10 feet of water. Please note the time you took your 
accelerometer off. 
16. Comments If you have anything that you would like to say that is relevant to your sleep feel 
free to write it here. 
 
 
Night form: Please complete before bed!
 !
Today’s Date:        
12a. How many times did 
you nap or doze? 
       
12b. How long in total did 
you nap or doze? 
       
13a. How many drinks 
containing alcohol did you 
have? 
13b. What time was your last 
drink? 
       
14a. How many caffeinated 
drinks (coffee, tea, soda, 
energy drinks) did you have? 
13b. What time was your last 
drink? 
       
15a. Did you take any over 
the counter or prescription 
medications to help you 
sleep? 
☐Yes ☐No ☐Yes ☐No ☐Yes ☐No ☐Yes ☐No ☐Yes ☐No ☐Yes ☐No ☐Yes ☐No 
15b. If so, please list the 
medications, dose, and time 
taken. 
 
 
       
16. Rate your experience of 
cognitive functioning today 
based on what is 
typical/average for you: 
-2: Much worse 
-1: Slightly worse 
0: Average 
1: Slightly better 
2: Much better 
 
___ Memory 
___ Attention 
___ Processing Speed 
___ Impulsivity 
___ Language 
 
___ Memory 
___ Attention 
___ Processing Speed 
___ Impulsivity 
___ Language 
 
___ Memory 
___ Attention 
___ Processing Speed 
___ Impulsivity 
___ Language 
 
___ Memory 
___ Attention 
___ Processing Speed 
___ Impulsivity 
___ Language 
 
___ Memory 
___ Attention 
___ Processing Speed 
___ Impulsivity 
___ Language 
 
___ Memory 
___ Attention 
___ Processing Speed 
___ Impulsivity 
___ Language 
 
___ Memory 
___ Attention 
___ Processing Speed 
___ Impulsivity 
___ Language 
 
17. Comments (if 
applicable): 
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Appendix B: Descriptive Questionnaire 
 
Study start date: ___________                                                                           Sex:  ☐Male    
☐Female       
 
Age: ___________                                                                               Handedness:  ☐Left      
☐Right  
 
Where did you hear about this study: __________________________________________   
 
What is the ethnicity with which you MOST CLOSELY identify? 
 
 □ Hispanic or Latino 
 □ Not Hispanic or Latino 
 
Do you consider yourself Hispanic or Latino? 
 
□ Yes 
 □ No 
 
What is your race/ethnicity (select all that apply)? 
 
□ Non-Hispanic White 
 □ Black (African American) 
 □ Black (Afro-Caribbean) 
 □ Black (African) 
□ Black (Other) 
 □ Hispanic/Latino (Mexican) 
 □ Hispanic/Latino (Puerto Rican) 
□ Hispanic/Latino (Cuban) 
□ Hispanic/Latino (Other Central American) 
□ Hispanic/Latino (Brazilian) 
 □ Hispanic/Latino (Other South American) 
□ Hispanic/Latino (Other) 
 □ Asian (Indian/Pakistani/Bangladeshi/Indian Subcontinent) 
 □ Asian (Arab/Persian/Middle-Eastern) 
 □ Asian (Chinese Taiwanese) 
□ Asian (Japanese) 
□ Asian (Korean) 
□ Asian (Southeast Asian – Vietnamese, Laotian, Thai, Hmong, etc.) 
□ Asian (Other) 
 □ American Indian/ Native American 
□ Alaskan Native 
 
  
EDUCATION 
 
Highest grade completed: 
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☐ Grade school (1-8 years) 
☐ High school (9-12 years) 
☐ College (13-16 years) 
☐ Masters (17-18) 
☐ J.D. (19 years) 
☐ Ph.D. (20 years) 
☐ M.D. (20 years) 
If other, please specify: ___________ 
 
Do you have a history of a learning disability? ☐No    ☐Yes    Explain: 
_________________________ 
 
 
OCCUPATIONAL INFORMATION 
 
What is your employment status? 
 
 □ Full time 
 □ Multiple jobs  
 □ Part time 
 □ Self-employed  
 □ Retired 
 □ Homemaker 
 □ Student 
 □ Unemployed less than 1 year 
 □ Unemployed greater than 1 year 
□ Unable to work 
 
Has this changed since your diagnosis? Same □ Different □  
Explain: __________________ 
 
Occupation ___________________________ 
 
If employed or in school full-time, please select the work schedule that you typically work. Select 
all that apply.  
 □ Primarily day schedule (9am-5pm)  
 □ Primarily evening shift (4pm to midnight) 
 □ Primarily night shift (Midnight to 8am)  
 □ Rotating shift  
 □ Not applicable 
 
 
MS HISTORY 
 
Date of diagnosis: _________________________ 
 
Years since symptoms onset: _________________________ 
 
Date of last exacerbation: _________________________ 
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Health 
 
 
MEDICATIONS 
 
 
 
 
 
 
  
Please rate your overall mental health on the scale below next to the statement that most closely 
describes you: 
□1 I am in excellent mental health  
□2 I have no mental health conditions  
□3 I have a chronic mental health condition, but it is stable and well managed  
□4 I have a chronic mental health condition, and it is not stable and well managed 
□5 I have multiple chronic mental health conditions, but they are stable and well managed  
□6 I have multiple chronic mental health conditions, and they are not stable and well managed 
 
Conditions: 
 
□Current  
□Past   
□No 
 
Depression      
Generalized Anxiety Disorder   
Obsessive Compulsive Disorder   
PTSD      
Schizophrenia      
Bipolar Disorder or Manic Depression  
Autism or Asperger’s    
ADD or ADHD     
Substance and/or alcohol Use or Dependence  
Eating Disorder (Bulimia or Anorexia) 
 
How many hours per week do you exercise on average ?______________ 
 
What kind of exercise do you typically do? 
 
 □ walking 
 □ running 
 □ weights 
 □ dancing 
 □ swimming  
 □ aerobics/cardio 
 □ yoga/pilates 
 □ sports (boxing, karate) 
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 □ biking 
 □ *other ______________ 
 
 
IMPAIRMENTS 
 
Physical difficulties ☐No    ☐Yes    Explain: 
_______________________________________________ 
 
Cognitive difficulties ☐No    ☐Yes    Explain: 
______________________________________________ 
 
Visual difficulties No Yes Explain: ☐No    ☐Yes    Explain: 
___________________________________ 
 
Problems with hearing: ☐No    ☐Yes    Explain: 
_____________________________________________ 
 
Have you ever been diagnosed or treated for the following: 
 
Depression: ☐Past ☐Current 
Anxiety: ☐Past ☐Current 
Bipolar Disorder: ☐Past ☐Current 
Substance Abuse: ☐Past ☐Current 
Other psychiatric: _______________________ ☐Past ☐Current 
 
 
SLEEP INFORMATION: 
 
Have you ever been diagnosed or treated for a sleep disorder: ☐No    ☐Yes    Explain: 
______________ 
 
______________________________________________________________________________
______ 
 
Do you have any sleep difficulties: ☐No    ☐Yes    Explain: 
___________________________________ 
 
______________________________________________________________________________
______ 
 
Do you ever take prescription or over the counter medications to help you sleep? ☐No    ☐Yes     
 
What do you take? _______________________________________ 
 
Dose? _________________________ 
 
How often do you take this? _______________________ 
 
When was the last time you took this medication? _______________________ 
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Figure 1. 
 
 
 
  
Figure 1. Proposed model of the relationship between sleep and cognitive function in MS. 
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